Sentences with phrase «new myeloma»
According to Cancer Research UK, each year Britain diagnoses 4,000 new Myeloma cases and 2,500 Myeloma sufferers die.
http://www.politics.co.uk/ Not exact matches
According to Loncar, U.S. pharma giant Johnson & Johnson (jnj) and Danish biotech partner Genmab stood above their peers during the conference with stellar new data for Darzalex, a treatment for multiple myeloma (a rare blood cancer) that was first approved last year.
Multiple myeloma drug Revlimid and anti-inflammatory Otezla have the potential to grow sales by double - digits throughout the remainder of the decade while also expanding into a number of new indications.
So far, its trials have shown it can improve outcomes when used alongside other multiple myeloma drugs and that could offer it some insulation if the market gets disrupted by new treatment approaches, such as gene therapy.
«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Health.
«Despite new therapies, it's virtually inevitable that a patient with multiple myeloma will experience relapse of the disease at some point,» said senior author Catriona Jamieson, MD, PhD, professor of medicine, Koman Family Presidential Endowed Chair in Cancer Research and chief of the Division of Regenerative Medicine at UC San Diego School of Medicine.
Using their new model, Jamieson, Crews and team found that two events converge to activate ADAR1 in multiple myeloma — a genetic abnormality and inflammatory cues from the surrounding bone marrow tissue.
Despite recent advances, including several new FDA - approved therapies for myeloma, the disease remains incurable, and nearly all patients eventually die from it.
«Stem cell transplantation for multiple myeloma: New data did not change conclusion.»
The new findings build on prior research from the Dhodapkar lab demonstrating that patients with Gaucher disease, an inherited lipid storage disorder, have a significant increased risk for developing myeloma; and the discovery of a subset of lipid - reactive immune cells, called type II NKT - TFH, that promote the development of plasma cells.
«These studies set the stage for newer approaches to lower the levels of these lipids in patients with Gaucher disease and others with precursors for myeloma.
In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana - Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment - resistant forms of the disease.
DeCicco - Skinner's research suggests a new approach for the treatment of multiple myeloma.
«In summary, these encouraging data build upon the real success of our translational efforts in myeloma over the last decade, and provide exciting new options with the real promise of improving patient outcome,» said Richardson, who is also the R.J. Corman professor at Harvard Medical School.
«Therefore, the targeting of Runx2 expression in multiple myeloma cells may represent a new therapeutic strategy for the treatment of aggressive multiple myeloma.»
«This new mechanism of Runx2 overexpression can give multiple myeloma cells a bone cell - like phenotype,» Yang said of the work by her lab and collaborators.
«When the multiple myeloma cells come to the new bone sites, the bone immune cells think, «This is one of our neighbor cells,» and therefore do not eliminate them.
New research shows that excess weight increases the risk that a benign blood disorder will progress into multiple myeloma, a cancer of the blood.
«The significance of this finding gives us a tentative approach to target this marker and could lead to new therapies for this subtype of myeloma.»
«Thanks to a deeper understanding of cancer biology, we have a potential new targeted therapy for multiple myeloma, and can better tailor treatment for kids with Wilms tumor.
A randomized phase III trial finding that a new monoclonal antibody, elotuzumab, added to standard therapy, extended the duration of remission for patients with relapsed multiple myeloma by about five months Findings from two phase III studies showing that children with Wilms tumor who have a specific chromosomal abnormality do better with a more intensive, augmented chemotherapy regimen
The new candidate myeloma genes we identified in the African - American population may have been overlooked because of the lack of diversity in previous genomic efforts.»
A new study published online by JAMA Oncology examines the assessment of minimal residual disease in patients newly treated for multiple myeloma as a factor in survival outcomes.
A new therapeutic approach tested by a team from Maisonneuve - Rosemont Hospital (CIUSSS - EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana - Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine.
«Our research highlights a potentially new mechanism of dinaciclib action, and raises the possibility that this agent could be a useful addition to current multiple myeloma and myeloid leukemia therapies.»
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple - myeloma patients.
Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).
«New pathway underlying multiple myeloma relapse.»
«We believe that the new criteria will rectify the situation where we were unable to use the considerable advances in multiple myeloma therapy prior to organ damage.
A new study by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) provides evidence that genetically modifying immune cells might effectively treat multiple myeloma, a disease that remains incurable and will account for an estimated 24,000 new cases and 11,100 deaths in 2014
The investigational treatment was combined with chemotherapy and an autologous stem cell transplant — a new strategy designed to target and kill the cells that give rise to myeloma cells.
The researcher team from the University of Birmingham, New Cross and Heartlands Hospitals compared the cellular chemistry of bone marrow and blood samples taken from patients with myeloma, patients with MGUS and healthy volunteers.
This research provides the basis for developing new and more targeted treatments and minimally invasive ways of identifying those MGUS patients at risk of progressing to myeloma.
A new class of drugs for blood cancers such as leukemia and multiple myeloma is showing promise.
Immunotherapies are a promising new strategy to fight multiple myeloma.
Yongwon Choi, with Ralph Steinman and others, identifies a new tumor necrosis factor family member TRANCE (later called RANKL), [i] and subsequently demonstrates its role in the immune and bone system, and also in bone - residing cancers such as multiple myelomas.
The new immune system that grows from the donor stem cells can recognize myeloma cells as «foreign» and kill them, which is known as the «graft - vs - myeloma» effect.
The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center...
Multiple myeloma is one of the major cancer types for which new immune - based cancer treatments are currently in development.
These patients were significantly underrepresented in trials of new treatments for lymphoma, CLL, and myeloma compared with the incidence of these diseases in that age group.
They fused mouse B cells — antibody - producing cells of the immune system — with human myeloma (also known as B cell cancer) cell lines in a new technique called hybridoma technology.
As a new member of the elite Multiple Myeloma Research Foundation, we have access to even more new treatments earlier than other facilities, and we are supporting the continued advancement of myeloma theMyeloma Research Foundation, we have access to even more new treatments earlier than other facilities, and we are supporting the continued advancement of myeloma themyeloma therapies.
While myeloma is not curable, it is treatable, especially at a top cancer center like UT Southwestern that has the newest therapies.
CAR T - cell therapy targeting B - cell maturation protein may be a new effective type of immunotherapy treatment for patients with multiple myeloma.
A study led by Helena Jernberg Wiklund, Uppsala University / SciLifeLab, shows how the protein EZH2 affects the development of multiple myeloma, and that inhibition of EZH2 could be used as a new strategy to treat the disease.
The purpose of this study is to identify the most appropriate dose of a new study drug (BAY 1251152) that may treat acute myeloid leukemia or multiple myeloma.
CRP Levels Before Transplant Linked With Survival in Multiple Myeloma: According to a new study, patients with an elevation in C - reactive protein (CRP) prior to an autologous stem cell transplantation (ASCT) for multiple myeloma experienced a worse overall survival (OSMyeloma: According to a new study, patients with an elevation in C - reactive protein (CRP) prior to an autologous stem cell transplantation (ASCT) for multiple myeloma experienced a worse overall survival (OSmyeloma experienced a worse overall survival (OS) rate.
Instead, newer trials have suggested that the use of minimal residual disease (MRD) status may be a valid surrogate outcomes for survival in patients with myeloma who achieved CR.
Clinical trials in GVHD, new drugs in leukemia, lymphoma and myeloma.